In 340 adults with IgA nephropathy on renin-angiotensin system inhibition, atrasentan vs placebo did not significantly slow eGFR decline at week 136 (key secondary endpoint): −7·5 vs −9·9 mL/min/1·73 m² (difference 2·4; p=0·057). Fluid retention: 14% vs 12%.
RCTn = 404
Heerspink et al. Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial